SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Minimal Clip Art Collage. Pop Vector Design Composition with bright bold geometric shapes, halftone objects for ad, animation etc
Approvals
First Commissioner’s Priority Review Approval Goes to Decades-Old Antibiotic
The Commissioner’s National Priority Voucher program was launched in June to shorten review times for companies that align with various national priorities, such as improving domestic drug production and supply.
December 10, 2025
 · 
2 min read
 · 
Tristan Manalac
Podcast
Weight Loss Waves, Pazdur’s Exit and FDA Instability, New Neuro Breakthroughs
Pfizer deals again in obesity space as Wave and Structure drop splashy weight loss results; what CDER Director Richard Pazdur’s sudden retirement means for biopharma; neuro diseases take center stage at CTAD; and more.
December 10, 2025
 · 
1 min read
 · 
Heather McKenzie
Hand with the ace of Spades playing card. Vintage color engraving stylized drawing. Vector illustration
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
December 10, 2025
 · 
1 min read
 · 
Annalee Armstrong
Hands holding red circle. Sensing energy between palms. Concept of human relation, togetherness, partnership, connection, contact or network. Design for banner, flyer, poster, cover or brochure.
Japan
Japanese Pharmas Looking Beyond Borders for M&A to US, EU
Long a quieter, locally focused industry, Japanese pharma giants are increasingly looking to the rest of the world for deals.
December 10, 2025
 · 
7 min read
 · 
Dan Samorodnitsky
Vector illustration of businessmen on a roller coaster ride bar graph
Regulatory
Regeneron Climbs Back After a Year of Regulatory, Manufacturing Misery
After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this summer—the lowest they’d been since early 2021. But they now sit higher than they did at the start of the year.
December 10, 2025
 · 
3 min read
 · 
Annalee Armstrong
Two businessmen negotiating with big speech bubbles
Rare diseases
Saol To Pitch Ultrarare Disease Drug as “Poster Child” for RDEP Program
Saol Therapeutics received a complete response letter for its pyruvate dehydrogenase complex deficiency treatment a week after the FDA unveiled its Rare Disease Evidence Principles program. On Dec. 18, in a Type A meeting, the biotech will attempt to convince the agency that its drug fits perfectly into the framework.
December 9, 2025
 · 
2 min read
 · 
Heather McKenzie
Relay race. Concept of teamwork. working together of business. Vector illustration
Clinical Research
Terns Climbs 10% As ‘Unprecedented’ Leukemia Data Beats Novartis’ Scemblix
TERN-701 more than doubled the response rate of Novartis’ rival approved therapy in an early-stage trial, sending the biotech’s shares flying.
December 9, 2025
 · 
3 min read
 · 
Annalee Armstrong
Shanghai.China-Feb.25th 2022: Pfizer company sign on office building. Pharmaceutical and biotechnology corporation
Obesity
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
Pfizer apparently had more in the tank after the high-profile battle to acquire Metsera earlier this fall. The company has licensed a new GLP-1 from YaoPharma.
December 9, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
FDA signage at its headquarters in Maryland
FDA
CAR-T Developers Will Need Randomized Trials as FDA Eyes Tighter Approval Requirements
For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including already-approved CAR T products.
December 9, 2025
 · 
2 min read
 · 
Tristan Manalac
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS